Abstract: Background: Congenital dysfibrinogenemia is characterized by reduced fibrinogen activity, but normal immunoreactive fibrinogen levels. Here, we present a novel case with an elevated risk of thrombosis.
Methods: Coagulation assays, gene analysis, in silico tools, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), fibrin polymerization, thrombin generation assay, and electron microscopy scanning were utilized to elucidate the pathogenic mechanism.
Results: The proband manifested with a normal immunologic fibrinogen (2.13 g/l) but reduced functional fibrinogen (0.39 g/l). Subsequent genetic analysis unveiled a novel heterozygous mutation, c.1030G>C (p.Asp318His), in the γ-chain D domain of fibrinogen, which was highly conserved in homologous species and led to enhanced thrombin generation capability. The ability of the proband's fibrinogen to polymerize was significantly impaired, with decreased final turbidity. Scanning electron microscopy indicated that the fibers of the proband were thinner than normal, with smaller pores. Thromboelastography (TEG) results demonstrated prolonged K time, decreased angle value, and a normal confidence interval value in the proband.
Conclusion: We present a novel case displaying the γAsp318His mutation, which resulted in dysfibrinogenemia.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
References: Pieters M, Wolberg AS. Fibrinogen and fibrin: an illustrated review. Res Pract Thromb Haemost 2019; 3:161–172.
Marchi R, Vilar R, Durual S, Goodyer M, Gay V, Neerman-Arbez M, Casini A. Fibrin clot properties to assess the bleeding phenotype in unrelated patients with hypodysfibrinogenemia due to novel fibrinogen mutations. Thromb Res 2021; 197:56–64.
Brennan SO, Davis RL. Substitution ((335Trp→Arg) in fibrinogen Fremantle causes diminished ( chain expression and increased sialic acid content. Thromb Haemost 2010; 104:274–1276.
Ivaškevičius V, Biswas A, Singh S, Stulpinaitė U, Reda S, Rühl H, et al. Fibrinogen Bonn (p. Arg510Cys) in the Aα-chain is associated with high risk of venous thrombosis. Hamostaseologie 2023; 43:440–446.
Jia K, Zeng M, Zheng X, Xie H, Yang L, Xie Y, Wang M. A novel fibrinogen mutation p.BβAla68Asp causes an inherited dysfibrinogenemia. Hamostaseologie 2023; 43:426–431.
Marin MJ, Mathew CM, Rajasekhar A, Zumberg M, Euliano TY, Winter WE, et al. Dysfibrinogenemia: discrepant results following infusion of purified fibrinogen. Blood Coagul Fibrinolysis 2023; 34:337–344.
Ramanan R, McFadyen JD, Perkins AC, Tran HA. Congenital fibrinogen disorders: strengthening genotype-phenotype correlations through novel genetic diagnostic tools. Br J Haematol 2023; 203:355–368.
Li Y, Ding B, Wang X, Ding Q. Congenital (hypo-)dysfibrinogenemia and bleeding: a systematic literature review. Thromb Res 2022; 217:36–47.
Casini A, Moerloose P, Neerman-Arbez M. One hundred years of congenital fibrinogen disorders. Semin Thromb Hemost 2022; 48:880–888.
Wolberg AS. Fibrinogen and fibrin: synthesis, structure, and function in health and disease. J Thromb Haemost 2023; 21:3005–3015.
Abdelghani E, Dawson J, Zajo K, Hallam M, Dunn A, Kumar R. Fibrinogen Columbus III: a novel c.963del frameshift mutation in the FGG gene resulting in hypofibrinogenemia with a bleeding phenotype. Pediatr Blood Cancer 2021; 68:e28713.
Casini A, de Moerloose P. How I treat dysfibrinogenemia. Blood 2021; 138:2021–2030.
Casini A, Neerman-Arbez M, Ariëns RA, de Moerloose P. Dysfibrinogenemia: from molecular anomalies to clinical manifestations and management. J Thromb Haemost 2015; 13:909–919.
Liao Z, Tang H, Xie Y, Duan X, Xu S, Liu C, et al. Fibrinogen Hangzhou: congenital dysfibrinogenemia caused by the novel missense mutation in FGG (γ308Asn→Thr). Clin Chim Acta 2014; 428:106–109.
Neerman-Arbez M, de Moerloose P, Casini A. Laboratory and genetic investigation of mutations accounting for congenital fibrinogen disorders. Semin Thromb Hemost 2016; 42:356–365.
Protein precipitation using ammonium sulfate. Curr Protoc Protein Sci. 2016;84:A.3F.1–A.3F.9.
Haverkate F, Samama M. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995; 73:151–161.
Liu CY, Nossel HL, Kaplan KL. The binding of thrombin by fibrin. J Biol Chem 1979; 254:10421–10425.
Casini A, Blondon M, Lebreton A, Koegel J, Tintillier V, de Maistre E, et al. Natural history of patients with congenital dysfibrinogenemia. Blood 2015; 125:553–561.
Processing Request
No Comments.